Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker-Zimmer Case Sets Up Tech Industry, Government Clash On Patent Damages Issue

This article was originally published in The Gray Sheet

Executive Summary

In a case going before the Supreme Court in less than three weeks, Stryker is asking the court to broaden the circumstances under which patent damages may be tripled, a position the Obama administration appears to support but one that is getting pushback from tech firms, and at least one device-maker, Medtronic.

You may also be interested in...

High Court Gives Stryker Second Shot At Enhanced Damages

The court’s ruling likely expands the circumstances under which patent-holders may be awarded enhanced damages by eliminating a strict test that had been imposed by the Federal Circuit.

In Case You Missed It: Top 10 Gray Sheet Stories In February

Our coverage of the highly anticipated release of the revised ISO 13485 international medical device quality systems standard attracted the most attention from Gray Sheet readers last month. Also popular: stories about FDA photography during facility inspections, European postmarket surveillance reforms, and policy updates focused on human factors.

Stryker, Zimmer Get Day In Supreme Court For Questions On Enhanced Patent Damages

The Justices were asked to review a Federal Circuit policy that limits the circumstances in which enhanced damages can be awarded in patent infringement cases for willful infringement.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts